Transforming Retinal Disease Care: Next-Generation Therapies for nAMD and DME to Reduce Burden and Optimize Outcomes
home / case-based-roundtable-series / transforming-retinal-disease-care-next-generation-therapies-for-namd-and-dme-to-reduce-burden
Dilsher S. Dhoot, MD discusses how second-generation anti-VEGF therapies like aflibercept 8mg and faricimab demonstrate superior efficacy and durability in treating neovascular AMD and DME cases, allowing treatment intervals to extend by 2-3 weeks, improving anatomical outcomes, and reducing patient treatment burden compared to first-generation agents.
New content coming soon.
